Abstract
Authors: Sabrina M. Scroggins (University of Iowa, Iowa City, Iowa) , Donna A. Santillan (University of Iowa, Iowa City, Iowa) , Jeremy A. Sandgren (University of Iowa, Iowa City, Iowa) , Gary L. Pierce (University of Iowa, Iowa City, Iowa) , Curt D. Sigmund (University of Iowa, Iowa City, Iowa) , Justin L. Grobe (University of Iowa, Iowa City, Iowa) , Mark K. Santillan (University of Iowa, Iowa City, Iowa)
The early pathogenesis of preeclampsia (PE) involves a systemic inflammatory immune response. Recent data demonstrate that increased circulating arginine vasopressin (AVP) in humans is predictive of PE and that infusion of AVP in mouse dams phenocopies the pregnancy-specific cardiovascular and immune alterations observed in human PE. Specifically, AVP suppresses anti-inflammatory cytokines and cells. Betamethasone (BMTZ), commonly given to women at risk for preterm birth, is both an AVP and immune response modulator. We hypothesize that early treatment with BMTZ will prevent the development of AVP-induced PE.
Keywords: Betamethasone, preeclampsia
How to Cite: Scroggins, S. M. , Santillan, D. A. , Sandgren, J. A. , Pierce, G. L. , Sigmund, C. D. , Grobe, J. L. & Santillan, M. K. (2018) “Betamethasone: a novel therapeutic intervention for preeclampsia”, Proceedings in Obstetrics and Gynecology. 8(3). doi: https://doi.org/10.17077/2154-4751.1432